Since their initial explosion onto the market, there is a growing pipeline demonstrating the promise of aptamer therapeutics across…

09/01/2023 Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer,…

As we come to the end of 2022 and our first year as a listed company, the year in review shows a clear theme of growth and expansion across…

Drugs of abuse tests require highly selective, robust assays. Aptamers are helping to deliver new assays for more sensitive and simpler tests. According to the UN Office on Drugs…

The ability to continuously monitor the concentration of specific molecules in the body is a long-sought goal of biomedical research. For this purpose, interstitial fluid (ISF) was proposed as…

DNA day on April 25th, celebrates major scientific achievements concerning DNA, in particular the completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix…

Why we do this. What the benefit is for you. Aptamers are increasingly being used across the life sciences in research, diagnostics and therapeutics. We have years of experience in…

Modified thymine bases, each containing a polymerizable group (either carboxymethylvinyl or acrylamide) at the 5-position, have been incorporated multiple times into an aptamer sequence allowing the sequence to act…

Last week the government released their new Life Sciences Vision. This 10-year strategy for the sector aims to ensure that the United Kingdom builds a supportive environment for…

04/03/2021 Aptamer Group, the developer of Optimer™ reagents and therapeutics, today announced the extension of their current agreement with AstraZeneca, a global biopharmaceutical company. This agreement will build upon the existing…